Combined low-dose DAC treatment and pharmacological DNMT1 inhibition has been demonstrated to ameliorate type 2 diabetes mellitus and halt the onset and progression of non-alcoholic fatty liver disease (NAFLD) by targeting and modulating macrophage polarization in adipose tissue (66, 67). Here, DNMT1 is linked to metabolic dysfunction-associated steatotic liver disease.